The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer

OBJECTIVE: To determine the efficacy, progression-free survival (PFS) and overall survival (OS) for the combination of intravenous bevacizumab and oral cyclophosphamide in heavily pretreated patients with recurrent ovarian carcinoma. METHODS: A retrospective review was performed for all patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Barber, Emma L., Zsiros, Emese, Lurain, John R., Rademaker, Alfred, Schink, Julian C., Neubauer, Nikki L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3714464/
https://www.ncbi.nlm.nih.gov/pubmed/23875076
http://dx.doi.org/10.3802/jgo.2013.24.3.258

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3714464/
https://www.ncbi.nlm.nih.gov/pubmed/23875076
http://dx.doi.org/10.3802/jgo.2013.24.3.258

Ejemplares similares